US › Healthcare

Nephros Inc (NEPH)

US · Healthcare · Medical Instruments & Supplies

$3.59+2.28%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$5.2M
Revenue YoY
+6.9%
Net profit
$140,000
Profit YoY
-74.9%
EPS
$0.01
EPS estimate
$0.01
Net margin
2.7%

EPS came in at 0.01 against a street estimate of 0.01 — a beat of 0.0%.

Key statistics

Market cap
$36.8M
P/E
48.4
Forward P/E
0.0
P/B
3.44
Book value
$0.99
EPS (TTM)
$0.07
52-week high
$6.42
52-week low
$2.66
50-day MA
$3.49
200-day MA
$4.02
Beta
1.49

Analyst view

Analysts rate Nephros Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $6.00.

Shareholding

Insiders
12.87%
Institutions
49.09%

Largest institutional holders

FundStake
Wexford Capital LP33.16%
Topline Capital Management LLC5.36%
Vanguard Capital Management, LLC1.83%
Petersen Flynn & Dinsmore Inc1.19%
Bard Associates Inc1.12%
Morgan Stanley - Brokerage Accounts1.02%
Renaissance Technologies Corp0.92%
Geode Capital Management, LLC0.67%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Nephros Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.